|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gapstur SM, Drope JM, Jacobs EJ, Teras LR,
McCullough ML, Douglas CE, Patel AV, Wender RC and Brawley OW: A
blueprint for the primary prevention of cancer: Targeting
established, modifiable risk factors. CA Cancer J Clin. 68:446–470.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Argueta EA and Moss SF: The prevention of
gastric cancer by Helicobacter pylori eradication. Curr Opin
Gastroenterol. 37:625–630. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gao S, Tan H and Li D: Oridonin suppresses
gastric cancer SGC-7901 cell proliferation by targeting the
TNF-alpha/androgen receptor/TGF-beta signalling pathway axis. J
Cell Mol Med. 27:2661–2674. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao S, Gang J, Yu M, Xin G and Tan H:
Computational analysis for identification of early diagnostic
biomarkers and prognostic biomarkers of liver cancer based on GEO
and TCGA databases and studies on pathways and biological functions
affecting the survival time of liver cancer. BMC Cancer.
21:7912021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang X, Wang W, Zhu W, Dong J, Cheng Y,
Yin Z and Shen F: Mechanisms and functions of long non-coding RNAs
at multiple regulatory levels. Int J Mol Sci. 20:55732019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bridges MC, Daulagala AC and Kourtidis A:
LNCcation: lncRNA localization and function. J Cell Biol.
220:e2020090452021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferrè F, Colantoni A and Helmer-Citterich
M: Revealing protein-lncRNA interaction. Brief Bioinform.
17:106–116. 2016. View Article : Google Scholar
|
|
9
|
Peng WX, Koirala P and Mo YY:
LncRNA-mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chi Y, Wang D, Wang J, Yu W and Yang J:
Long non-coding RNA in the pathogenesis of cancers. Cells.
8:10152019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bach DH and Lee SK: Long noncoding RNAs in
cancer cells. Cancer Lett. 419:152–166. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li LJ, Chai Y, Guo XJ, Chu SL and Zhang
LS: Effects of endoplasmic reticulum stress on autophagy and
apoptosis of human leukemia cells via inhibition of the
PI3K/AKT/mTOR signaling pathway. Mol Med Rep. 17:7886–7892.
2018.PubMed/NCBI
|
|
13
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hoxhaj G and Manning BD: The PI3K-AKT
network at the interface of oncogenic signalling and cancer
metabolism. Nat Rev Cancer. 20:74–88. 2020. View Article : Google Scholar :
|
|
15
|
Fruman DA, Chiu H, Hopkins BD, Bagrodia S,
Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell.
170:605–635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu F, Na L, Li Y and Chen L: Roles of the
PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and
tumours. Cell Biosci. 10:542020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iyer MK, Niknafs YS, Malik R, Singhal U,
Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et
al: The landscape of long noncoding RNAs in the human
transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nelson BR, Makarewich CA, Anderson DM,
Winders BR, Troupes CD, Wu F, Reese AL, McAnally JR, Chen X,
Kavalali ET, et al: A peptide encoded by a transcript annotated as
long noncoding RNA enhances SERCA activity in muscle. Science.
351:271–275. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakano Y, Isobe K, Kobayashi H, Kaburaki
K, Isshiki T, Sakamoto S, Takai Y, Tochigi N, Mikami T, Iyoda A, et
al: Clinical importance of long non-coding RNA LINC00460 expression
in EGFR-mutant lung adenocarcinoma. Int J Oncol. 56:243–257.
2020.
|
|
20
|
Zhou H, Feng B, Abudoureyimu M, Lai Y, Lin
X, Tian C, Huang G, Chu X and Wang R: The functional role of long
non-coding RNAs and their underlying mechanisms in drug resistance
of non-small cell lung cancer. Life Sci. 261:1183622020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu H, Wu J, Yu X, Zhou J, Yu H and Ma L:
Long non-coding RNA MALAT1 enhances the apoptosis of cardiomyocytes
through autophagy inhibition by regulating TSC2-mTOR signaling.
Biol Res. 52:582019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kang X, Kong F, Huang K, Li L, Li Z, Wang
X, Zhang W and Wu X: LncRNA MIR210HG promotes proliferation and
invasion of non-small cell lung cancer by upregulating methylation
of CACNA2D2 promoter via binding to DNMT1. Onco Targets Ther.
12:3779–3790. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tian H, Pan J, Fang S, Zhou C, Tian H, He
J, Shen W, Meng X, Jin X and Gong Z: LncRNA DPP10-AS1 promotes
malignant processes through epigenetically activating its cognate
gene DPP10 and predicts poor prognosis in lung cancer patients.
Cancer Biol Med. 18:675–692. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ali T and Grote P: Beyond the
RNA-dependent function of LncRNA genes. Elife. 9:e605832020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang CL, Zhu KP and Ma XL: Antisense
lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by
increasing the expression of FOXC2. Cancer Lett. 396:66–75. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mariner PD, Walters RD, Espinoza CA,
Drullinger LF, Wagner SD, Kugel JF and Goodrich JA: Human Alu RNA
is a modular transacting repressor of mRNA transcription during
heat shock. Mol Cell. 29:499–509. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Robinson EK, Covarrubias S and Carpenter
S: The how and why of lncRNA function: An innate immune
perspective. Biochim Biophys Acta Gene Regul Mech. 1863:1944192020.
View Article : Google Scholar :
|
|
28
|
Wan Y, Yao D, Fang F, Wang Y, Wu G and
Qian Y: LncRNA WT1-AS downregulates lncRNA UCA1 to suppress
non-small cell lung cancer and predicts poor survival. BMC Cancer.
21:1042021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li L, Huang C, He Y, Sang Z, Liu G and Dai
H: Knockdown of long non-coding RNA GAS5 increases mir-23a by
targeting ATG3 involved in autophagy and cell viability. Cell
Physiol Biochem. 48:1723–1734. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang L, Peng X, Jin H and Liu J: Long
non-coding RNA PVT1 promotes autophagy as ceRNA to target ATG3 by
sponging microRNA-365 in hepatocellular carcinoma. Gene.
697:94–102. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ao R, Guan L, Wang Y and Wang JN:
Silencing of COL1A2, COL6A3, and THBS2 inhibits gastric cancer cell
proliferation, migration, and invasion while promoting apoptosis
through the PI3k-Akt signaling pathway. J Cell Biochem.
119:4420–4434. 2018. View Article : Google Scholar
|
|
32
|
Li Z, Dong H, Li M, Wu Y, Liu Y, Zhao Y,
Chen X and Ma M: Honokiol induces autophagy and apoptosis of
osteosarcoma through PI3K/Akt/mTOR signaling pathway. Mol Med Rep.
17:2719–2723. 2018.
|
|
33
|
Tamaskovic R, Schwill M, Nagy-Davidescu G,
Jost C, Schaefer DC, Verdurmen WP, Schaefer JV, Honegger A and
Plückthun A: Intermolecular biparatopic trapping of ErbB2 prevents
compensatory activation of PI3K/AKT via RAS-p110 crosstalk. Nat
Commun. 7:116722016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Revathidevi S and Munirajan AK: Akt in
cancer: Mediator and more. Semin Cancer Biol. 59:80–91. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shariati M and Meric-Bernstam F: Targeting
AKT for cancer therapy. Expert Opin Investig Drugs. 28:977–988.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shiwarski DJ, Darr M, Telmer CA, Bruchez
MP and Puthenveedu MA: PI3K class II α regulates δ-opioid receptor
export from the trans-Golgi network. Mol Biol Cell. 28:2202–2219.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z,
Li W, Hu J, Lu C and Liu Y: PI3K/AKT pathway as a key link
modulates the multidrug resistance of cancers. Cell Death Dis.
11:7972020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mayer IA and Arteaga CL: The PI3K/AKT
pathway as a target for cancer treatment. Annu Rev Med. 67:11–28.
2016. View Article : Google Scholar
|
|
39
|
Tian L, Zhao Z, Xie L and Zhu J:
MiR-361-5p suppresses chemoresistance of gastric cancer cells by
targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget.
9:4886–4896. 2017. View Article : Google Scholar
|
|
40
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lien EC, Dibble CC and Toker A: PI3K
signaling in cancer: Beyond AKT. Curr Opin Cell Biol. 45:62–71.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
M JR and S V: BMI1 and PTEN are key
determinants of breast cancer therapy: A plausible therapeutic
target in breast cancer. Gene. 678:302–311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Brown JS and Banerji U: Maximising the
potential of AKT inhibitors as anti-cancer treatments. Pharmacol
Ther. 172:101–115. 2017. View Article : Google Scholar
|
|
44
|
Chai C, Song LJ, Han SY, Li XQ and Li M:
MicroRNA-21 promotes glioma cell proliferation and inhibits
senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT
signaling pathway. CNS Neurosci Ther. 24:369–380. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang L, Liu Z, Dong Y and Kong L: E2F2
drives glioma progression via PI3K/AKT in a PFKFB4-dependent
manner. Life Sci. 276:1194122021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miricescu D, Totan A, Stanescu-Spinu II,
Badoiu SC, Stefani C and Greabu M: PI3K/AKT/mTOR signaling pathway
in breast cancer: From molecular landscape to clinical aspects. Int
J Mol Sci. 22:1732020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ediriweera MK, Tennekoon KH and Samarakoon
SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer:
Biological and therapeutic significance. Semin Cancer Biol.
59:147–160. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang W, Zhou Q, Wei Y, Da M, Zhang C,
Zhong J, Liu J and Shen J: The exosome-mediated PI3k/Akt/mTOR
signaling pathway in cervical cancer. Int J Clin Exp Pathol.
12:2474–2484. 2019.
|
|
49
|
Fattahi S, Amjadi-Moheb F, Tabaripour R,
Ashrafi GH and Akhavan-Niaki H: PI3K/AKT/mTOR signaling in gastric
cancer: Epigenetics and beyond. Life Sci. 262:1185132020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Narayanankutty A: PI3K/Akt/mTOR pathway as
a therapeutic target for colorectal cancer: A review of preclinical
and clinical evidence. Curr Drug Targets. 20:1217–1226. 2019.
View Article : Google Scholar
|
|
51
|
Wang L, Li S, Luo H, Lu Q and Yu S: PCSK9
promotes the progression and metastasis of colon cancer cells
through regulation of EMT and PI3K/AKT signaling in tumor cells and
phenotypic polarization of macrophages. J Exp Clin Cancer Res.
41:3032022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yang J, Qin G, Luo M, Chen J, Zhang Q, Li
L, Pan L and Qin S: Reciprocal positive regulation between Cx26 and
PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC
cells via GJIC-independent induction of EMT. Cell Death Dis.
6:e18292015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Oh S, Kim H, Nam K and Shin I: Silencing
of Glut1 induces chemoresistance via modulation of
Akt/GSK-3β/β-catenin/survivin signaling pathway in breast cancer
cells. Arch Biochem Biophys. 636:110–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kumar D, Haldar S, Gorain M, Kumar S,
Mulani FA, Yadav AS, Miele L, Thulasiram HV and Kundu GC:
Epoxyazadiradione suppresses breast tumor growth through
mitochondrial depolarization and caspase-dependent apoptosis by
targeting PI3K/Akt pathway. BMC Cancer. 18:522018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chang CZ, Wu SC, Chang CM, Lin CL and Kwan
AL: Arctigenin, a potent ingredient of arctium lappa L., induces
endothelial nitric oxide synthase and attenuates subarachnoid
hemorrhage-induced vasospasm through PI3K/Akt pathway in a rat
model. Biomed Res Int. 2015:4902092015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cheng TC, Din ZH, Su JH, Wu YJ and Liu CI:
Sinulariolide suppresses cell migration and invasion by inhibiting
matrix metal-loproteinase-2/-9 and urokinase through the
PI3K/AKT/mTOR signaling pathway in human bladder cancer cells. Mar
Drugs. 15:2382017. View Article : Google Scholar
|
|
57
|
Yu M, Qi B, Xiaoxiang W, Xu J and Liu X:
Baicalein increases cisplatin sensitivity of A549 lung
adenocarcinoma cells via PI3K/Akt/NF-κB pathway. Biomed
Pharmacother. 90:677–685. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tan YT, Lin JF, Li T, Li JJ, Xu RH and Ju
HQ: LncRNA-mediated posttranslational modifications and
reprogramming of energy metabolism in cancer. Cancer Commun (Lond).
41:109–120. 2021. View Article : Google Scholar
|
|
59
|
Winkle M, El-Daly SM, Fabbri M and Calin
GA: Noncoding RNA therapeutics-challenges and potential solutions.
Nat Rev Drug Discov. 20:629–651. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chia NY and Tan P: Molecular
classification of gastric cancer. Ann Oncol. 27:763–769. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu HT, Ma RR, Lv BB, Zhang H, Shi DB, Guo
XY, Zhang GH and Gao P: LncRNA-HNF1A-AS1 functions as a competing
endogenous RNA to activate PI3K/AKT signalling pathway by sponging
miR-30b-3p in gastric cancer. Br J Cancer. 122:1825–1836. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Dai Q, Zhang T, Pan J and Li C: LncRNA
UCA1 promotes cisplatin resistance in gastric cancer via recruiting
EZH2 and activating PI3K/AKT pathway. J Cancer. 11:3882–3892. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang L, Bo X, Yi X, Xiao X, Zheng Q, Ma L
and Li B: Exosome-transferred LINC01559 promotes the progression of
gastric cancer via PI3K/AKT signaling pathway. Cell Death Dis.
11:7232020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wu Q, Ma J, Wei J, Meng W, Wang Y and Shi
M: FOXD1-AS1 regulates FOXD1 translation and promotes gastric
cancer progression and chemoresistance by activating the
PI3K/AKT/mTOR pathway. Mol Oncol. 15:299–316. 2021. View Article : Google Scholar
|
|
67
|
Zhao W, Zhao X, Xu M, Cheng Z and Zhang Z:
Knockdown of LINC01279 suppresses gastric cancer proliferation and
migration by inhibiting PI3K/Akt/mTOR signaling pathway. J Oncol.
2022:62289822022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Han L, Hao Y, Wang J, Wang Z, Yang H and
Wu X: Knockdown of LINC02465 suppresses gastric cancer cell growth
and metastasis Via PI3K/AKT pathway. Hum Gene Ther Clin Dev.
30:19–28. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Cheng C, Qin Y, Zhi Q, Wang J and Qin C:
Knockdown of long non-coding RNA HOTAIR inhibits cisplatin
resistance of gastric cancer cells through inhibiting the PI3K/Akt
and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int
J Biol Macromol. 107:2620–2629. 2018. View Article : Google Scholar
|
|
70
|
Wang Q, Mao X, Luo F and Wang J: LINC00511
promotes gastric cancer progression by regulating SOX4 and
epigenetically repressing PTEN to activate PI3K/AKT pathway. J Cell
Mol Med. 25:9112–9127. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Huang Y, Zhang J, Hou L, Wang G, Liu H,
Zhang R, Chen X and Zhu J: LncRNA AK023391 promotes tumorigenesis
and invasion of gastric cancer through activation of the PI3K/Akt
signaling pathway. J Exp Clin Cancer Res. 36:1942017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhu K, Ren Q and Zhao Y: lncRNA MALAT1
overexpression promotes proliferation, migration and invasion of
gastric cancer by activating the PI3K/AKT pathway. Oncol Lett.
17:5335–5342. 2019.PubMed/NCBI
|
|
73
|
Dai Q, Zhang T and Li C: LncRNA MALAT1
regulates the cell proliferation and cisplatin resistance in
gastric cancer via PI3K/AKT pathway. Cancer Manag Res.
12:1929–1939. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hu Y, Zhang Y, Ding M and Xu R: Long
noncoding RNA TMPO-AS1/miR-126-5p/BRCC3 axis accelerates gastric
cancer progression and angiogenesis via activating PI3K/Akt/mTOR
pathway. J Gastroenterol Hepatol. 36:1877–1888. 2021. View Article : Google Scholar
|
|
75
|
Du DX, Lian DB, Amin BH and Yan W: Long
non-coding RNA CRNDE is a novel tumor promoter by modulating
PI3K/AKT signal pathways in human gastric cancer. Eur Rev Med
Pharmacol Sci. 21:5392–5398. 2017.PubMed/NCBI
|
|
76
|
Zhuang SH, Meng CC, Fu JJ and Huang J:
Long non-coding RNA ELFN1-AS1-mediated ZBTB16 inhibition augments
the progression of gastric cancer by activating the PI3K/AKT axis.
Kaohsiung J Med Sci. 38:621–632. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ma F, An K and Li Y: Silencing of long
non-coding RNA-HCG18 inhibits the tumorigenesis of gastric cancer
through blocking PI3K/Akt pathway. Onco Targets Ther. 13:2225–2234.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yao L, Ye PC, Tan W, Luo YJ, Xiang WP, Liu
ZL, Fu ZM, Lu F, Tang LH and Xiao JW: Decreased expression of the
long non-coding RNA HOXD-AS2 promotes gastric cancer progression by
targeting HOXD8 and activating PI3K/Akt signaling pathway. World J
Gastrointest Oncol. 12:1237–1254. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Li X, Yan X, Wang F, Yang Q, Luo X, Kong J
and Ju S: Down-regulated lncRNA SLC25A5-AS1 facilitates cell growth
and inhibits apoptosis via miR-19a-3p/PTEN/PI3K/AKT signalling
pathway in gastric cancer. J Cell Mol Med. 23:2920–2932. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Li C, Liang G, Yang S, Sui J, Wu W, Xu S,
Ye Y, Shen B, Zhang X and Zhang Y: LncRNA-LOC101928316 contributes
to gastric cancer progression through regulating PI3K-Akt-mTOR
signaling pathway. Cancer Med. 8:4428–4440. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liang LC, Liu LQ, Liu L, Liu DL, He YR,
Wan X, Zhu ZQ, Zhang BG, Liu SJ, Wu H and Hu L: Long non-coding RNA
BX357664 inhibits gastric cancer progression by sponging
miR-183a-3p to regulate the PTEN expression and PI3K/AKT pathway.
Food Chem Toxicol. 150:1120692021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Li JF, Li WH, Xue LL and Zhang Y: Long
non-coding RNA PICART1 inhibits cell proliferation by regulating
the PI3K/AKT and MAPK/ERK signaling pathways in gastric cancer. Eur
Rev Med Pharmacol Sci. 23:588–597. 2019.PubMed/NCBI
|
|
83
|
Cen D, Huang H, Yang L, Guo K and Zhang J:
Long noncoding RNA STXBP5-AS1 inhibits cell proliferation,
migration, and invasion through inhibiting the PI3K/AKT signaling
pathway in gastric cancer cells. Onco Targets Ther. 12:1929–1936.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Chen P, Zhao X, Wang H, Zheng M, Wang Q
and Chang W: The down-regulation of lncRNA PCAT18 promotes the
progression of gastric cancer via MiR-107/PTEN/PI3K/AKT signaling
pathway. Onco Targets Ther. 12:11017–11031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Hu J, Wang M, Yang Y, Xing Y and Li S:
LncRNA DLEU2 silencing impedes the migration, invasion and EMT in
gastric cancer cell by suppressing PI3K/AKT signaling pathway.
Immunopharmacol Immunotoxicol. 44:719–731. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wong MCS, Huang J, Lok V, Wang J, Fung F,
Ding H and Zheng ZJ: Differences in incidence and mortality trends
of colorectal cancer worldwide based on sex, age, and anatomic
location. Clin Gastroenterol Hepatol. 19:955–966.e61. 2021.
View Article : Google Scholar
|
|
87
|
Zhang F, Su T and Xiao M: RUNX3-regulated
circRNA METTL3 inhibits colorectal cancer proliferation and
metastasis via miR-107/PER3 axis. Cell Death Dis. 13:5502022.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Song W, Mei JZ and Zhang M: Long noncoding
RNA PlncRNA-1 promotes colorectal cancer cell progression by
regulating the PI3K/Akt signaling pathway. Oncol Res. 26:261–268.
2018. View Article : Google Scholar
|
|
89
|
Yun WK, Hu YM, Zhao CB, Yu DY and Tang JB:
HCP5 promotes colon cancer development by activating AP1G1 via
PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 23:2786–2793.
2019.PubMed/NCBI
|
|
90
|
Zhang X, Yi S, Xing G, Wu H, Zhu Y, Guo X
and Zhang L: FOXCUT promotes the proliferation and invasion by
activating FOXC1/PI3K/AKT pathway in colorectal cancer. Cancer
Manag Res. 12:6269–6278. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Wang Y, Kuang H, Xue J, Liao L, Yin F and
Zhou X: LncRNA AB073614 regulates proliferation and metastasis of
colorectal cancer cells via the PI3K/AKT signaling pathway. Biomed
Pharmacother. 93:1230–1237. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Yang P, Li J, Peng C, Tan Y, Chen R, Peng
W, Gu Q, Zhou J, Wang L, Tang J, et al: TCONS_00012883 promotes
proliferation and metastasis via DDX3/YY1/MMP1/PI3K-AKT axis in
colorectal cancer. Clin Transl Med. 10:e2112020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Cui Z, Han B, Wang X, Li Z, Wang J and Lv
Y: Long non-coding RNA TTN-AS1 promotes the proliferation and
invasion of colorectal cancer cells by activating miR-497-mediated
PI3K/Akt/mTOR signaling. Onco Targets Ther. 12:11531–11539. 2019.
View Article : Google Scholar
|
|
94
|
Pei Q, Liu GS, Li HP, Zhang Y, Xu XC, Gao
H, Zhang W and Li T: Long noncoding RNA SNHG14 accelerates cell
proliferation, migration, invasion and suppresses apoptosis in
colorectal cancer cells by targeting miR-944/KRAS axis through
PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 23:9871–9881.
2019.PubMed/NCBI
|
|
95
|
Duan Q, Cai L, Zheng K, Cui C, Huang R,
Zheng Z, Xie L, Wu C, Yu X and Yu J: lncRNA KCNQ1OT1 knockdown
inhibits colorectal cancer cell proliferation, migration and
invasiveness via the PI3K/AKT pathway. Oncol Lett. 20:601–610.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Zhang JJ, Xu WR, Chen B, Wang YY, Yang N,
Wang LJ and Zhang YL: The up-regulated lncRNA DLX6-AS1 in
colorectal cancer promotes cell proliferation, invasion and
migration via modulating PI3K/AKT/mTOR pathway. Eur Rev Med
Pharmacol Sci. 23:8321–8331. 2019.PubMed/NCBI
|
|
97
|
Fang J, Yang J, Chen H, Sun W, Xiang L and
Feng J: Long non-coding RNA LBX2-AS1 predicts poor survival of
colon cancer patients and promotes its progression via regulating
miR-627-5p/RAC1/PI3K/AKT pathway. Hum Cell. 35:1521–1534. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Feng W, Li B, Wang J, Zhang H, Liu Y, Xu
D, Cheng K and Zhuang J: Long non-coding RNA LINC00115 contributes
to the progression of colorectal cancer by targeting miR-489-3p via
the PI3K/AKT/mTOR pathway. Front Genet. 11:5676302020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Li Y, Zeng C, Hu J, Pan Y, Shan Y, Liu B
and Jia L: Long non-coding RNA-SNHG7 acts as a target of miR-34a to
increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in
colorectal cancer progression. J Hematol Oncol. 11:892018.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Liu B, Pan S, Xiao Y, Liu Q, Xu J and Jia
L: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer
progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway.
J Exp Clin Cancer Res. 37:3162018. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Lei Y, Wang YH, Wang XF and Bai J:
LINC00657 promotes the development of colon cancer by activating
PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 25:24602021.PubMed/NCBI
|
|
102
|
Meng S, Jian Z, Yan X, Li J and Zhang R:
LncRNA SNHG6 inhibits cell proliferation and metastasis by
targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer.
Mol Med Rep. 20:2541–2548. 2019.PubMed/NCBI
|
|
103
|
Hu J, Shan Y, Ma J, Pan Y, Zhou H, Jiang L
and Jia L: LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal
cancer progression by regulating α-2,3 sialylation via PI3K/Akt
signaling. Int J Cancer. 145:450–460. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hao B, Wen H, Sun Y, Le Z, Zhang Z, Liu M
and Hu T: LncRNA-CASC7 inhibits the proliferation and migration of
colon cancer by negatively regulating the PI3K/Akt signaling
pathway. J Gastrointest Oncol. 12:2803–2813. 2021. View Article : Google Scholar
|
|
105
|
Zhang H, Zhang G, Liu H, Shan Y and Zhang
X: RP11-462C24.1 suppresses proliferation and invasion of
colorectal carcinoma cells by regulating HSP70 through PI3K/AKT
signaling pathway. Hum Cell. 34:132–151. 2021. View Article : Google Scholar
|
|
106
|
Mattiuzzi C and Lippi G: Current cancer
epidemiology. J Epidemiol Glob Health. 9:217–222. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Cheng K, Cai N, Zhu J, Yang X, Liang H and
Zhang W: Tumor-associated macrophages in liver cancer: From
mechanisms to therapy. Cancer Commun (Lond). 42:1112–1140. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Han K, Li C, Zhang X and Shang L: DUXAP10
inhibition attenuates the proliferation and metastasis of
hepatocellular carcinoma cells by regulation of the Wnt/β-catenin
and PI3K/Akt signaling pathways. Biosci Rep. 39:BSR201814572019.
View Article : Google Scholar
|
|
109
|
Zhuang J, He S, Wang G, Wang G, Ni J,
Zhang S, Ye Y and Xia W: Long noncoding RNA FGFR3-AS1 promotes
hepatocellular carcinoma carcinogenesis via modulating the PI3K/AKT
pathway. Oncol Res. 26:1257–1265. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zheng YF, Zhang XY and Bu YZ: LINC01133
aggravates the progression of hepatocellular carcinoma by
activating the PI3K/AKT pathway. J Cell Biochem. 120:4172–4179.
2019. View Article : Google Scholar
|
|
111
|
Han Y, Chen M, Wang A and Fan X:
STAT3-induced upregulation of lncRNA CASC11 promotes the cell
migration, invasion and epithelial-mesenchymal transition in
hepatocellular carcinoma by epigenetically silencing PTEN and
activating PI3K/AKT signaling pathway. Biochem Biophys Res Commun.
508:472–479. 2019. View Article : Google Scholar
|
|
112
|
Yue H, Wu K, Liu K, Gou L, Huang A and
Tang H: LINC02154 promotes the proliferation and metastasis of
hepatocellular carcinoma by enhancing SPC24 promoter activity and
activating the PI3K-AKT signaling pathway. Cell Oncol (Dordr).
45:447–462. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Chen Z, Zhou ZY, He CC, Zhang JL, Wang J
and Xiao ZY: Down-regulation of LncRNA NR027113 inhibits cell
proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in
hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 22:7222–7232.
2018.PubMed/NCBI
|
|
114
|
Song XZ, Ren XN, Xu XJ, Ruan XX, Wang YL
and Yao TT: LncRNA RHPN1-AS1 promotes cell proliferation, migration
and invasion through targeting miR-7-5p and activating
PI3K/AKT/mTOR pathway in hepatocellular carcinoma. Technol Cancer
Res Treat. 19:15330338209570232020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Zhang W, Liang F, Li Q, Sun H, Li F, Jiao
Z and Lei J: LncRNA MIR205HG accelerates cell proliferation,
migration and invasion in hepatoblastoma through the activation of
MAPK signaling pathway and PI3K/AKT signaling pathway. Biol Direct.
17:22022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Huang JL, Cao SW, Ou QS, Yang B, Zheng SH,
Tang J, Chen J, Hu YW, Zheng L and Wang Q: The long non-coding RNA
PTTG3P promotes cell growth and metastasis via up-regulating PTTG1
and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol
Cancer. 17:932018. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Tang Q, Zheng X and Zhang J: Long
non-coding RNA CRNDE promotes heptaocellular carcinoma cell
proliferation by regulating PI3K/Akt/β-catenin signaling. Biomed
Pharmacother. 103:1187–1193. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Song Q, Zhang H, He J, Kong H, Tao R,
Huang Y, Yu H, Zhang Z, Huang Z, Wei L, et al: Long non-coding RNA
LINC00473 acts as a microRNA-29a-3p sponge to promote
hepatocellular carcinoma development by activating Robo1-dependent
PI3K/AKT/mTOR signaling pathway. Ther Adv Med Oncol.
12:17588359209378902020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Wu JH, Tian XY, An QM, Guan XY and Hao CY:
LINC00963 promotes hepatocellular carcinoma progression by
activating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci.
22:1645–1652. 2018.PubMed/NCBI
|
|
120
|
Hou Y, Chen K, Liao R, Li Y, Yang H and
Gong J: LINC01419-mediated epigenetic silencing of ZIC1 promotes
metastasis in hepatocellular carcinoma through the PI3K/Akt
signaling pathway. Lab Invest. 101:570–587. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zhong F, Liu S, Hu D and Chen L: LncRNA
AC099850.3 promotes hepatocellular carcinoma proliferation and
invasion through PRR11/PI3K/AKT axis and is associated with
patients prognosis. J Cancer. 13:1048–1060. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Shen Q, Jiang S, Wu M, Zhang L, Su X and
Zhao D: LncRNA HEIH confers cell sorafenib resistance in
hepatocellular carcinoma by regulating miR-98-5p/PI3K/AKT pathway.
Cancer Manag Res. 12:6585–6595. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Peng N, He J, Li J, Huang H, Huang W, Liao
Y and Zhu S: Long noncoding RNA MALAT1 inhibits the apoptosis and
autophagy of hepatocellular carcinoma cell by targeting the
microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell Int. 20:1652020.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zhou W, Wang J, Zhang J, Wang Y, Jiang L,
Guo T, Luo B, Xu Q and Huang Y: LncRNA NCK1-AS1 aggravates
hepatocellular carcinoma by the miR-22-3p/YARS axis to activate
PI3K/AKT signaling. J Gastrointestin Liver Dis. 31:48–59. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Ma ZJ, Wang Y, Li HF, Liu MH, Bi FR, Ma L,
Ma H and Yan HL: LncZEB1-AS1 regulates hepatocellular carcinoma
bone metastasis via regulation of the miR-302b-EGFR-PI3K-AKT axis.
J Cancer. 11:5118–5128. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Li S, Qi Y, Huang Y, Guo Y, Huang T and
Jia L: Exosome-derived SNHG16 sponging miR-4500 activates HUVEC
angiogenesis by targeting GALNT1 via PI3K/Akt/mTOR pathway in
hepatocellular carcinoma. J Physiol Biochem. 77:667–682. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Wang X, Dong K, Jin Q, Ma Y, Yin S and
Wang S: Upregulation of lncRNA FER1L4 suppresses the proliferation
and migration of the hepatocellular carcinoma via regulating
PI3K/AKT signal pathway. J Cell Biochem. 120:6781–6788. 2019.
View Article : Google Scholar
|
|
128
|
Sun L, Zhou J and Sun C: MicroRNA-211-5p
enhances analgesic effect of dexmedetomidine on inflammatory
visceral pain in rats by suppressing ERK signaling. J Mol Neurosci.
68:19–28. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Luo LH, Jin M, Wang LQ, Xu GJ, Lin ZY, Yu
DD, Yang SL, Ran RZ, Wu G and Zhang T: Long noncoding RNA TCL6
binds to miR-106a-5p to regulate hepatocellular carcinoma cells
through PI3K/AKT signaling pathway. J Cell Physiol. 235:6154–6166.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Wolpin BM: Pancreatic cancer. Hematol
Oncol Clin North Am. 29:13–14. 2015. View Article : Google Scholar
|
|
131
|
Zhao Z and Liu W: Pancreatic cancer: A
review of risk factors, diagnosis, and treatment. Technol Cancer
Res Treat. 19:15330338209621172020. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Luo C, Lin K, Hu C, Zhu X, Zhu J and Zhu
Z: LINC01094 promotes pancreatic cancer progression by sponging
miR-577 to regulate LIN28B expression and the PI3K/AKT pathway. Mol
Ther Nucleic Acids. 26:523–535. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Qiao X, Lv SX, Qiao Y, Li QP, Ye B, Wang
CC and Miao L: Long noncoding RNA ABHD11-AS1 predicts the prognosis
of pancreatic cancer patients and serves as a promoter by
activating the PI3K-AKT pathway. Eur Rev Med Pharmacol Sci.
22:8630–8639. 2018.PubMed/NCBI
|
|
134
|
Zhang Y, Zhang R, Luo G and Ai K: Long
noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT
signaling pathway in pancreatic ductal adenocarcinoma. J Cancer.
9:2713–2722. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Gu L, Zhang J, Shi M, Zhan Q, Shen B and
Peng C: lncRNA MEG3 had anti-cancer effects to suppress pancreatic
cancer activity. Biomed Pharmacother. 89:1269–1276. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Harada K, Rogers JE, Iwatsuki M, Yamashita
K, Baba H and Ajani JA: Recent advances in treating oesophageal
cancer. F1000Res. 9:F1000 Faculty Rev-11892020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Li Y, Yang B, Ma Y, Peng X, Wang Z, Sheng
B, Wei Z, Cui Y and Liu Z: Phosphoproteomics reveals therapeutic
targets of esophageal squamous cell carcinoma. Signal Transduct
Target Ther. 6:3812021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Reichenbach ZW, Murray MG, Saxena R,
Farkas D, Karassik EG, Klochkova A, Patel K, Tice C, Hall TM, Gang
J, et al: Clinical and translational advances in esophageal
squamous cell carcinoma. Adv Cancer Res. 144:95–135. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Xu J, Ma J, Guan B, Li J, Wang Y and Hu S:
LncRNA HCP5 promotes malignant cell behaviors in esophageal
squamous cell carcinoma via the PI3K/AKT/mTOR signaling. Cell
Cycle. 20:1374–1388. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Wang G, Sun J, Zhao H and Li H: Long
non-coding RNA (lncRNA) growth arrest specific 5 (GAS5) suppresses
esophageal squamous cell carcinoma cell proliferation and migration
by inactivating phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian
target of rapamycin (mTOR) signaling pathway. Med Sci Monit.
24:7689–7696. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Fu X, Cui G, Liu S and Zhao S: Linc01014
regulates gefitinib resistance in oesophagus cancer via
EGFR-PI3K-AKT-mTOR signalling pathway. J Cell Mol Med.
24:1670–1675. 2020. View Article : Google Scholar
|
|
142
|
Baiu I and Visser B: Gallbladder cancer.
JAMA. 320:12942018. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Hickman L and Contreras C: Gallbladder
cancer: Diagnosis, surgical management, and adjuvant therapies.
Surg Clin North Am. 99:337–355. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Roa JC, García P, Kapoor VK, Maithel SK,
Javle M and Koshiol J: Gallbladder cancer. Nat Rev Dis Primers.
8:692022. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Wei CX, Wong H, Xu F, Liu Z, Ran L and
Jiang RD: IRF4-induced upregulation of lncRNA SOX2-OT promotes cell
proliferation and metastasis in cholangiocarcinoma by regulating
SOX2 and PI3K/AKT signaling. Eur Rev Med Pharmacol Sci.
22:8169–8178. 2018.PubMed/NCBI
|
|
146
|
Wang C, Mao ZP, Wang L, Wu GH, Zhang FH,
Wang DY and Shi JL: Long non-coding RNA MALAT1 promotes
cholangiocarcinoma cell proliferation and invasion by activating
PI3K/Akt pathway. Neoplasma. 64:725–731. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Zhang Y, Zhang L, Lu S, Xiang Y, Zeng C,
He T, Ding Y and Wang W: Long non-coding RNA CASC15 promotes
intrahepatic cholangiocarcinoma possibly through Inducing
PRDX2/PI3K/AKT axis. Cancer Res Treat. 53:184–198. 2021. View Article : Google Scholar :
|
|
148
|
Cai Q, Wang ZQ, Wang SH, Li C, Zhu ZG,
Quan ZW and Zhang WJ: Upregulation of long non-coding RNA LINC00152
by SP1 contributes to gallbladder cancer cell growth and tumor
metastasis via PI3K/AKT pathway. Am J Transl Res. 8:4068–4081.
2016.PubMed/NCBI
|
|
149
|
Cheung PK, Ma MH, Tse HF, Yeung KF, Tsang
HF, Chu MKM, Kan CM, Cho WCS, Ng LBW, Chan LWC and Wong SCC: The
applications of metabolomics in the molecular diagnostics of
cancer. Expert Rev Mol Diagn. 19:785–793. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Wu L and Qu X: Cancer biomarker detection:
Recent achievements and challenges. Chem Soc Rev. 44:2963–2997.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Goyal B, Yadav SRM, Awasthee N, Gupta S,
Kunnumakkara AB and Gupta SC: Diagnostic, prognostic, and
therapeutic significance of long non-coding RNA MALAT1 in cancer.
Biochim Biophys Acta Rev Cancer. 1875:1885022021. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Nemeth K, Bayraktar R, Ferracin M and
Calin GA: Non-coding RNAs in disease: From mechanisms to
therapeutics. Nat Rev Genet. 25:211–232. 2024. View Article : Google Scholar
|
|
153
|
Rebbeck TR, Burns-White K, Chan AT, Emmons
K, Freedman M, Hunter DJ, Kraft P, Laden F, Mucci L, Parmigiani G,
et al: Precision prevention and early detection of cancer:
Fundamental principles. Cancer Discov. 8:803–811. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Borrebaeck CAK: Precision diagnostics:
Moving towards protein biomarker signatures of clinical utility in
cancer. Nat Rev Cancer. 17:199–204. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Xia M, Zhu W, Tao C, Lu Y and Gao F:
LncRNA LASTR promote lung cancer progression through the
miR-137/TGFA/PI3K/ AKT axis through integration analysis. J Cancer.
13:1086–1096. 2022. View Article : Google Scholar :
|
|
156
|
Xu D, Yu J, Zhuang S, Zhang S, Hong Z and
Yuan C: Overexpression of long non-coding RNA LINC00982 suppresses
cell proliferation and tumor growth of papillary thyroid carcinoma
through PI3K-ATK signaling pathway. Biosci Rep. 39:BSR201912102019.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Liu ZB, Wang JA and Lv RQ: Downregulation
of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by
PI3K-AKT signaling pathways and indicates good prognosis. Eur Rev
Med Pharmacol Sci. 23:1418–1427. 2019.PubMed/NCBI
|
|
158
|
Ma L, Kuai WX, Sun XZ, Lu XC and Yuan YF:
Long noncoding RNA LINC00265 predicts the prognosis of acute
myeloid leukemia patients and functions as a promoter by activating
PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 22:7867–7876.
2018.PubMed/NCBI
|
|
159
|
Gao XF, He HQ, Zhu XB, Xie SL and Cao Y:
LncRNA SNHG20 promotes tumorigenesis and cancer stemness in
glioblastoma via activating PI3K/Akt/mTOR signaling pathway.
Neoplasma. 66:532–542. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Li C, Feng S and Chen L: MSC-AS1 knockdown
inhibits cell growth and temozolomide resistance by regulating
miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway. Mol Cell
Biochem. 476:699–713. 2021. View Article : Google Scholar :
|
|
161
|
Zhou J, Xu N, Liu B, Wang C, He Z, Lenahan
C, Tang W, Zeng H and Guo H: lncRNA XLOC013218 promotes cell
proliferation and TMZ resistance by targeting the PIK3R2-mediated
PI3K/AKT pathway in glioma. Cancer Sci. 113:2681–2692. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Zhang X, Niu W, Mu M, Hu S and Niu C: Long
non-coding RNA LPP-AS2 promotes glioma tumorigenesis via
miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop. J Exp Clin Cancer Res.
39:1962020. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Swain SM, Shastry M and Hamilton E:
Targeting HER2-positive breast cancer: Advances and future
directions. Nat Rev Drug Discov. 22:101–126. 2023. View Article : Google Scholar
|
|
164
|
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot
W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, et al:
Trastuzumab deruxtecan versus trastuzumab emtansine in patients
with HER2-positive metastatic breast cancer: Updated results from
DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet.
401:105–117. 2023. View Article : Google Scholar
|
|
165
|
Liu J, Chen M, Ma L, Dang X and Du G:
LncRNA GAS5 suppresses the proliferation and invasion of
osteosarcoma cells via the miR-23a-3p/PTEN/PI3K/AKT pathway. Cell
Transplant. 29:9636897209530932020. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Gao S, Tan H and Gang J: Inhibition of
hepatocellular carcinoma cell proliferation through regulation of
the Cell Cycle, AGE-RAGE, and Leptin signaling pathways by a
compound formulation comprised of andrographolide, wogonin, and
oroxylin A derived from Andrographis Paniculata(Burm.f.) Nees. J
Ethnopharmacol. 329:1180012024. View Article : Google Scholar
|
|
167
|
Gourd K: ESMO gastrointestinal cancers
congress 2024. Lancet Oncol. 25:9612024. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang
Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, et al: Long noncoding RNA
MALAT1 suppresses breast cancer metastasis. Nat Genet.
50:1705–1715. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Cantile M, Di Bonito M, Cerrone M, Collina
F, De Laurentiis M and Botti G: Long non-coding RNA HOTAIR in
breast cancer therapy. Cancers (Basel). 12:11972020. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Bhat AA, Afzal O, Afzal M, Gupta G, Thapa
R, Ali H, Hassan Almalki W, Kazmi I, Alzarea SI, Saleem S, et al:
MALAT1: A key regulator in lung cancer pathogenesis and therapeutic
targeting. Pathol Res Pract. 253:1549912024. View Article : Google Scholar
|
|
171
|
Loewen G, Jayawickramarajah J, Zhuo Y and
Shan B: Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol.
7:902014. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Nanni S, Aiello A, Salis C, Re A, Cencioni
C, Bacci L, Pierconti F, Pinto F, Ripoli C, Ostano P, et al:
Metabolic reprogramming by Malat1 depletion in prostate cancer.
Cancers (Basel). 13:152020. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Li T, Liu N, Gao Y, Quan Z, Hao Y, Yu C,
Li L, Yuan M, Niu L, Luo C and Wu X: Long noncoding RNA HOTAIR
regulates the invasion and metastasis of prostate cancer by
targeting hepaCAM. Br J Cancer. 124:247–258. 2021. View Article : Google Scholar :
|
